` ACHV (Achieve Life Sciences Inc) vs S&P 500 Comparison - Alpha Spread

ACHV
vs
S&P 500

Over the past 12 months, ACHV has underperformed S&P 500, delivering a return of -42% compared to the S&P 500's +14% growth.

Stocks Performance
ACHV vs S&P 500

Loading
ACHV
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ACHV vs S&P 500

Loading
ACHV
S&P 500
Difference
www.alphaspread.com

Performance By Year
ACHV vs S&P 500

Loading
ACHV
S&P 500
Add Stock

Competitors Performance
Achieve Life Sciences Inc vs Peers

S&P 500
ACHV
ABBV
AMGN
GILD
VRTX
Add Stock

Achieve Life Sciences Inc
Glance View

Market Cap
127.7m USD
Industry
Biotechnology

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).

ACHV Intrinsic Value
1.01 USD
Overvaluation 61%
Intrinsic Value
Price
Back to Top